# A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

> **NCT04221477** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 271 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** MMF
- **DRUG:** Prednisone
- **DRUG:** Placebo
- **DRUG:** Methylprednisolone
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT04221477
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-10
- **Primary completion:** 2024-08-15
- **Final completion:** 2031-03-02
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221477, "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04221477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*